CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome

about

RASSF1A hypermethylation is associated with ASXL1 mutation and indicates an adverse outcome in non-M3 acute myeloid leukemia.

P2860

Q41545370-38645978-3FAE-46EA-90B8-AADA40936CC7

P2860

CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome

Item

http://www.wikidata.org/entity/Q37327786

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

CTNNA1 hypermethylation, a fre ...... ciated with an adverse outcome

@en

CTNNA1 hypermethylation, a fre ...... iated with an adverse outcome.

@nl

type

Item

label

CTNNA1 hypermethylation, a fre ...... ciated with an adverse outcome

@en

CTNNA1 hypermethylation, a fre ...... iated with an adverse outcome.

@nl

prefLabel

CTNNA1 hypermethylation, a fre ...... ciated with an adverse outcome

@en

CTNNA1 hypermethylation, a fre ...... iated with an adverse outcome.

@nl

P1476

CTNNA1 hypermethylation, a fre ...... ciated with an adverse outcome

@en

P2093

Chengbin Wang

http://www.w3.org/2001/XMLSchema#string

Haoqing Duan

http://www.w3.org/2001/XMLSchema#string

Hui Zhang

http://www.w3.org/2001/XMLSchema#string

Junzhong Sun

http://www.w3.org/2001/XMLSchema#string

Li Gao

http://www.w3.org/2001/XMLSchema#string

Mianyang Li

http://www.w3.org/2001/XMLSchema#string

Yigai Ma

http://www.w3.org/2001/XMLSchema#string

Zhenling Li

http://www.w3.org/2001/XMLSchema#string

P2860

New answers to old questions from genome-wide maps of DNA methylation in hematopoietic cells

Myeloid malignancies: mutations, models and management

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.

The role of mutations in epigenetic regulators in myeloid malignancies.

Acute myeloid leukaemia in adults.

DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies

The Frequency and clinical significance of IDH1 mutations in Chinese acute myeloid leukemia patients

P304

31454-31465

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.8962

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27129146

http://www.w3.org/2001/XMLSchema#string

P932

5058770

http://www.w3.org/2001/XMLSchema#string

CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome

about

P2860

P2860

CTNNA1 hypermethylation, a frequent event in acute myeloid leukemia, is independently associated with an adverse outcome

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932